Web Watch

Share this article:
Television as an advertising medium is losing its edge. According to a recent McKinsey & Co. report, there are half as many viewers of primetime broadcast television as ithere were10 years ago. But despite this decline in viewership, television advertisers have actually increased their investment in the medium by almost 40% during the last decade. One wonders how long it will take before these advertisers tire of paying more money to reach fewer people.

Considering how teenagers consume media, it won't be long before television ad dollars shift to other media. Teens now spend half as much time watching television as their parents and spend 600% more time online.

Young adults (ages 18–26) already are online more than they watch television and tend to be early adopters of new technology, according to Forrester Research. People in this age group are also heavy users of electronic gadgets, and are more interested in blogs, podcasts and mobile web advertisements.

If marketing dollars follow eyeballs, the media mix over the next few years will include less broadcast television combined with more new media.

There's evidence that this is happening already. Big advertisers like J&J, Coca Cola, Proctor & Gamble and Chrysler have either decided not to participate in the network television upfront market or increased their online and wireless spending to extend the impact of their 30-second television spots.

The real challenge is to leverage what each medium does best and build a more intelligent media plan by integrating television, radio, Internet, wireless, print and even outdoor advertising.
If you're now experimenting to find out what works best, you're in good company. If you're still on the sidelines, it's time to get in the game.

Dan McKillen is president of the HealthDay news service

Share this article:
close

Next Article in News

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.